Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection

New England Journal of Medicine

Volumn 332, Issue 9, 1995, Pages 567-575

  Kovacs, Joseph A ^a   Baseler, Michael ^b   Dewar, Robin J ^b   Vogel, Susan ^c   Davey, Richard T ^c   Falloon, Judith ^c   Polis, Michael A ^c   Walker, Robert E ^c   Stevens, Randy ^b   Salzman, Norman P ^b   Metcalf, Julia A ^c   Masur, Henry ^a   Lane, H Clifford ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Frederick ^*  (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; DIDANOSINE; HLA DR ANTIGEN; IBUPROFEN; INTERLEUKIN 2 RECEPTOR; PARACETAMOL; PETHIDINE; RECOMBINANT INTERLEUKIN 2; TRICHOSANTHIN; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV INFECTIONS; HUMAN; INTERLEUKIN-2; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028912032     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199503023320904     Document Type: Article

References (43)

1. Fischl MA, Richman DD, Grieco MH, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191
2. Yarchoan R, Mitsuya H, Thomas RV, In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 1989; 245: 412-415
3. Merigan TC, Skowron G, Bozzette SA, Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989; 110: 189-194
4. Meng TC, Fischl MA, Boota AM, Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992; 116: 13-20
5. Yarchoan R, Lietzau JA, Nguyen BY, A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169: 9-17
6. Lane HC, Zunich KM, Wilson W, Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1990; 113: 512-519
7. Lang JM, Touraine JL, Trepo C, Randomised, double-blind, placebo-controlled trial of ditiocarb sodium (‘Imuthiol’) in human immunodeficiency virus infection. Lancet 1988; 2: 702-706
8. Pedersen C, Sandstrom E, Petersen CS, The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990; 322: 1757-1763.
9. Lane HC, Davey V, Kovacs JA, Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-811
10. Lane HC, Davey RT Jr., Sherwin SA, A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 1989; 9: 351-361
11. Lane HC, Siegel JP, Rook AH, Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod 1984; 3: 512-516
12. Schwartz DH, Skowron G, Merigan TC Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991; 4: 11-23
13. Mazza P, Bocchia M, Tumietto F, Recombinant interleukin-2 (rIL-2) in acquired immune deficiency syndrome (AIDS): preliminary report in patients with lymphoma associated with HIV infection. Eur J Haematol 1992; 49: 1-6
14. Murray HW, Squires KE, Gassyuk-Botev E, DePamphilis JK Interleukin-2 treatment, interferon-gamma induction, and AIDS monocyte activation. Am J Med 1992; 93: 234-234
15. Teppler H, Kaplan G, Smith K, Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-298
16. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987; 3: 115-124
17. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169: 981-989
18. Smith KA Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-1176.
19. Rook AH, Masur H, Lane HC, Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72: 398-403
20. Lane HC, Kovacs JA, Feinberg J, Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1218-1222.
21. Lane HC, Masur H, Gelmann EP, Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med 1985; 78: 417-422
22. Vasudevachari MB, Salzman NP, Woll DR, Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. J Clin Immunol 1993; 13: 185-192
23. Davey RT Jr., Dewar RL, Reed GF, Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc Natl Acad Sci U S A 1993; 90: 5608-5612.
24. Pachl CA, Kern DG, Sheridan PJ, et al. Quantitative detection of HIV RNA in plasma using a signal amplification probe assay. In: Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 11-14, 1992. Washington, D.C.: American Society of Microbiology, 1992:318. abstract.
25. Urdea MS, Wilber JC, Yeghiazarian T, Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 1993; 7: Suppl 2: S11-S14
26. Dewar RL, Highbarger HC, Sarmiento MD, Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994; 170: 1172-1179.
27. Siegel JP, Puri RK Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704
28. Lotze MT, Matory YL, Rayner AA, Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764-2772.
29. Lane HC, Falloon J, Walker RE, Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma: a phase II randomized, placebo-controlled trial. Ann Intern Med 1989; 111: 41-50 [Erratum, Ann Intern Med 1990;112:388.]
30. Farace F, Angevin E, Escudier B, Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. Int J Cancer 1993; 54: 741-747
31. Landay A, Ohlsson-Wilhelm B, Giorgi JV Application of flow cytometry to the study of HIV infection. AIDS 1990; 4: 479-497
32. Giorgi JV, Detels R T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989; 52: 10-18
33. Stites DP, Casavant CH, McHugh TM, Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol 1986; 38: 161-177
34. Kimoto M, Fathman CG Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation. J Exp Med 1980; 152: 759-770
35. Cohen DI, Tani Y, Tian H, Boone E, Samelson LE, Lane HC Participation of tyrosine phosphorylation in the cytopathic effect of human immunodeficiency virus-1. Science 1992; 256: 542-545
36. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175: 331-340
37. Fan J, Bass HZ, Fahey JL Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993; 151: 5031-5040.
38. Groux H, Monte D, Plouvier B, Capron A, Ameisen JC CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-gamma and accessory cells. Eur J Immunol 1993; 23: 1623-1629.
39. Shearer GM, Clerici M T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Chem Immunol 1992; 54: 21-43
40. Clerici M, Hakim FT, Venzon DJ, Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993; 91: 759-765
41. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177: 483-492
42. Caligiuri MA, Murray C, Robertson MJ, Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-132
43. Piatak M Jr., Saag MS, Yang LC, High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-1754.